Rafael Holdings, Inc.

Rafael Holdings, Inc. filed its quarterly report (10-Q) for the period ending April 30, 2026. The company reported a net loss of $4.23 million for the third quarter, a slight improvement from the $4.78 million loss in the same period last year. Total revenue decreased to $179,000 from $362,000 year-over-year. For the nine-month period, the net loss widened to $20.46 million from $18.43 million, while revenue increased to $630,000 from $567,000. Research and development expenses saw a significant increase. Cash and cash equivalents decreased substantially.

Rafael Holdings, Inc. announced its financial results for the third quarter ended April 30, 2026. The company reported a net loss of $4.2 million, or $0.08 per share, compared to a net loss of $4.8 million, or $0.19 per share, in the prior year period. Research and development expenses increased due to the consolidation of Cyclo Therapeutic's expenses following an acquisition. The company also announced the completion of the last patient last visit for its pivotal Phase 3 TransportNPC™ trial and expects to submit an NDA in the second half of calendar 2026.

Rafael Holdings, Inc. announced the completion of the last patient's final 96-week study visit in its pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C. The company anticipates announcing topline data from the main study cohort and submitting a New Drug Application (NDA) in the second half of 2026, having already completed a pre-NDA meeting with the FDA. Additionally, the FDA has acknowledged the company's US Expanded Access Program.

Rafael Holdings, Inc. announced the completion of the pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC). Topline data from the study, which involved 94 patients globally, is expected in the second half of 2026. The company has already held a pre-NDA meeting with the FDA and plans to submit its New Drug Application (NDA) in the same period, aiming for an expedited path to market.

Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (MIT). This agreement covers U.S. Patent No. 12285440, which pertains to the use of cyclodextrins in treating Alzheimer's Disease patients who carry an ApoE4 genetic mutation. This deal could enhance Cyclo Therapeutics' pipeline in neurodegenerative diseases.

Rafael Holdings' subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (MIT) for U.S. Patent No. 12285440. This license covers the use of cyclodextrins, including Trappsol® Cyclo™, in Alzheimer's Disease patients carrying the ApoE4 genetic mutation, which is present in 50-70% of AD patients. The agreement strengthens the company's intellectual property and aims to accelerate a potential breakthrough by addressing the underlying pathology of AD through improved cholesterol transport in the brain.